Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 1
2000 1
2002 1
2006 1
2007 2
2008 1
2009 3
2010 7
2011 5
2012 14
2013 7
2014 7
2015 8
2016 12
2017 19
2018 13
2019 13
2020 16
2021 15
2022 19
2023 15
2024 21
2025 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

189 results

Results by year

Filters applied: . Clear all
Page 1
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA; RUBY Investigators. Mirza MR, et al. N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27. N Engl J Med. 2023. PMID: 36972026 Clinical Trial.
Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S, van Stein R, Sikorska K, Barton D, Perrin L, Brennan D, Zivanovic O, Mosgaard BJ, Fagotti A, Colombo PE, Sonke G, Driel WJV; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group. Koole S, et al. Int J Gynecol Cancer. 2020 Jun;30(6):888-892. doi: 10.1136/ijgc-2020-001231. Epub 2020 Mar 23. Int J Gynecol Cancer. 2020. PMID: 32205449 Free PMC article.
Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study.
Eerkens AL, Brummel K, Vledder A, Paijens ST, Requesens M, Loiero D, van Rooij N, Plat A, Haan FJ, Klok P, Yigit R, Roelofsen T, de Lange NM, Klomp R, Church D, Ter Elst A, Wardenaar R, Spierings D, Foijer F, Koelzer VH, Bosse T, Bart J, Jalving M, Reyners AKL, de Bruyn M, Nijman HW. Eerkens AL, et al. Among authors: reyners akl. Nat Commun. 2024 Sep 3;15(1):7695. doi: 10.1038/s41467-024-52098-8. Nat Commun. 2024. PMID: 39227583 Free PMC article. Clinical Trial.
Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology - an analysis of the closed cohorts of a multicentre prospective study.
van der Kleij MBA, Guchelaar NAD, Meertens M, Westerdijk K, Giraud EL, Bleckman RF, Groenland SL, van Eerden RAG, Imholz ALT, Vulink AJE, Otten HM, Fiebrich-Westra HB, Lubberman FJE, Desar IME, Moes DAR, Touw DJ, Koolen SLW, Gelderblom H, Reyners AKL, van Erp NP, Mathijssen RHJ, Huitema ADR; Dutch Pharmacology Oncology Group (DPOG); Steeghs N. van der Kleij MBA, et al. Among authors: reyners akl. Br J Cancer. 2024 Sep;131(5):843-851. doi: 10.1038/s41416-024-02789-2. Epub 2024 Jul 6. Br J Cancer. 2024. PMID: 38971952 Free PMC article.
Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial.
Lorusso D, Oaknin A, Borges GS, Damian F, Ottevanger N, Van Gorp T, Paiva CE, Kroep JR, Kim YM, Kim HS, Lee JK, Denys H, Lalisang R, De Melo AC, Redondo A, Reyners AKL, Mora P, Closset C, Melief CJM, Hooftman L, Jamil S, Boersma L, Yoo SY, Seebach F, Lowy I, Fury MG, Mathias M, Colombo N. Lorusso D, et al. Among authors: reyners akl. Gynecol Oncol. 2025 May;196:28-35. doi: 10.1016/j.ygyno.2025.03.019. Epub 2025 Mar 27. Gynecol Oncol. 2025. PMID: 40154184 Free article. Clinical Trial.
Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs; A practical and universal tool for management.
van Leeuwen RWF, le Comte M, Reyners AKL, van den Tweel A, van Vlijmen B, Kwee W, Wensveen B, Steeghs N, Visser O, van Gelder T, Jansman FGA. van Leeuwen RWF, et al. Among authors: reyners akl. Semin Oncol. 2022 Apr;49(2):119-129. doi: 10.1053/j.seminoncol.2022.03.002. Epub 2022 Mar 30. Semin Oncol. 2022. PMID: 35397932 Free article. Review.
Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis.
Paoletti X, Lewsley LA, Daniele G, Cook A, Yanaihara N, Tinker A, Kristensen G, Ottevanger PB, Aravantinos G, Miller A, Boere IA, Fruscio R, Reyners AKL, Pujade-Lauraine E, Harkin A, Pignata S, Kagimura T, Welch S, Paul J, Karamouza E, Glasspool RM; Gynecologic Cancer InterGroup (GCIG) Meta-analysis Committee. Paoletti X, et al. Among authors: reyners akl. JAMA Netw Open. 2020 Jan 3;3(1):e1918939. doi: 10.1001/jamanetworkopen.2019.18939. JAMA Netw Open. 2020. PMID: 31922558 Free PMC article.
189 results